Search

everythinglearnresearchcommunity

for

Search:↓

A new product, a retinoic acid solution (0.3%), is available to enhance minoxidil products like Rogaine and Kirkland by converting them into a tretinoin-containing solution for improved hair loss treatment. One unit of the product is enough for a year's supply.

A 42-year-old is using dutasteride, oral and topical minoxidil, ketoconazole, and a dermaroller for hair loss, with noticeable progress after six months. They are questioning if further gains are possible and considering stopping the dermaroller, as advised that future improvements may only involve hair thickening.

A 27-year-old is experiencing significant hair loss despite using a combination of 0.5mg dutasteride daily, topical minoxidil, nizoral shampoo, and vitamin D optimization, and is now starting zinc supplementation. Suggestions include considering other causes, possibly increasing dutasteride dosage, switching to oral minoxidil, or maintaining the current regimen and reassessing in six months.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

A 43-year-old from Thailand shares progress after 1 month using topical finasteride, minoxidil, tretinoin cream, and weekly microneedling for diffused thinning. Users compliment his appearance and suggest he doesn't need treatment.

The user used finasteride but stopped due to side effects, then used topical minoxidil for 13 months, and later added KX826/pyrilutamide for 8 months. They experienced shedding after starting pyrilutamide and use minoxidil and KX826 once daily.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

DutchFella1993 has been using a lotion with finasteride and minoxidil for hair regrowth with some success and is considering using ketoconazole shampoo daily to reduce scalp itchiness. There's concern about the harshness of daily shampooing and twice-daily lotion application, and one reply suggests that daily use of ketoconazole may damage hair and questions its effectiveness, while also noting that once-daily minoxidil application is sufficient.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

A 30-year-old female with telogen effluvium and androgenetic alopecia is using spironolactone, oral minoxidil, vitamin D, iron sulfate, and a hairmax laser band. She seeks recommendations for a dermastamp or derma roller, advised to use no higher than 0.5 mm.

The conversation discusses the effectiveness of topical tretinoin as a monotherapy for hair loss, with users suggesting it may not be as effective as minoxidil or finasteride. The original poster is considering other options like a phenol peel and is concerned about the risks of derma rolling.

A user expressed disappointment that their hair loss worsened after 11 months using topical finasteride with TrichoSol, despite no side effects and initial signs of improvement. They asked for advice and opinions on their treatment and alternatives, with suggestions including switching to oral finasteride or dutasteride, starting minoxidil, and addressing their seborrheic dermatitis with different shampoos or medical advice.

A user shared their positive experience with a 4-in-1 topical solution containing finasteride, minoxidil, ketoconazole, and biotin, along with weekly microneedling using a 1.2mm dermastamp. The user reported no noticeable side effects and mentioned that the biotin likely doesn't contribute to hair growth.

Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.

A user shared their 11-year journey with alopecia, using finasteride, dutasteride, and a hair transplant. They encouraged others not to panic, noting that hair miniaturization can take over 15 years to complete.

The conversation is about the availability of gt20029 for hair loss treatment, indicating that it will not be available for purchase soon. No specific treatments were discussed.

The user is experiencing intense hair shedding all over the scalp after applying pyrilutamide to the hairline and taking oral castor oil. They are also using topical finasteride and latanoprost, but are unsure which treatment is causing the shedding.

A user reported positive hair growth using a regimen of oral finasteride, minoxidil, Dr. Pen, keto shampoo, and a Capillus 272 LLLT cap. Other users debated the effectiveness of the LLLT cap, with some attributing the success to the combined treatments rather than the cap alone.

A user shared progress pictures after using a topical solution containing Minoxidil 5%, Tretinoin, and Azelaic acid for two months. The conversation discusses the effectiveness of this treatment for hair loss.

Topical tretinoin applied to the face may exacerbate hair loss in some individuals, potentially triggering conditions like frontal fibrosing alopecia. Experiences vary, with some users reporting no impact on hair, while others experience significant hair loss.

The conversation discusses a hair loss and scalp care routine involving ciclopirox shampoo, benzoyl peroxide, clindamycin gel, clobetasol propionate, and calcipotriol to manage seborrheic dermatitis, folliculitis, and inflammation. It also touches on the role of diet and other treatments like oral minoxidil and pioglitazone for scalp health.

A user successfully improved their hairline after 15 months using topical minoxidil and dutasteride. Some commenters question the necessity of treatment given the user's original hair condition, while others support early intervention.

PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

The conversation is about hair regrowth progress using topical finasteride 0.1%, minoxidil 10%, ketoconazole shampoo, and weekly microneedling. The user plans to continue the treatment for another year to assess its effectiveness.

OP had a doctor appointment, was advised to try B vitamins and change shampoo for hair loss, and may consider Finasteride if no improvement. Users suggest seeing a dermatologist directly, as vitamins likely won't help much with AGA.

The conversation is about a person experiencing treatment-resistant androgenic alopecia despite using high doses of dutasteride and minoxidil, along with other treatments like microneedling and purilutamide. Suggestions include considering a hair transplant, checking medication authenticity, and exploring other treatments like RU58841 or topical estradiol.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.